Aditya Puri Net Worth

The estimated Net Worth of Aditya Puri is at least $122 millier dollars as of 9 September 2016. Aditya Puri owns over 1,472,803 units of ViewRay stock worth over $121,919 and over the last 8 years Aditya sold VRAY stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Aditya Puri VRAY stock SEC Form 4 insiders trading

Aditya has made over 1 trades of the ViewRay stock since 2016, according to the Form 4 filled with the SEC. Most recently Aditya bought 1,472,803 units of VRAY stock worth $4,344,769 on 9 September 2016.

The largest trade Aditya's ever made was buying 1,472,803 units of ViewRay stock on 9 September 2016 worth over $4,344,769. On average, Aditya trades about 245,467 units every 0 days since 2016. As of 9 September 2016 Aditya still owns at least 4,876,745 units of ViewRay stock.

You can see the complete history of Aditya Puri stock trades at the bottom of the page.

What's Aditya Puri's mailing address?

Aditya's mailing address filed with the SEC is C/O VIEWRAY, INC.,, 2 THERMO FISHER WAY, OAKWOOD VILLAGE, OH, 44146.

Insiders trading at ViewRay

Over the last 9 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun et Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.

What does ViewRay do?

mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving

Complete history of Aditya Puri stock trades at ViewRay

ViewRay executives and stock owners

ViewRay executives and other stock owners filed with the SEC include:

• Scott William Drake,
  Pres, CEO & Director
• Dr. James F. Dempsey,
  Chief Scientific Officer
• Zachary William Stassen,
  Chief Financial Officer
• Amanda Sequira,
  Sr. VP of Clinical, Quality & Regulatory
• Paul Ziegler Jr.,
  Chief Commercial Officer
• Dr. Martin Fuss,
  Chief Medical Officer
• Robert Michael Fuchs,
  Chief HR Officer
• Karen Hackstaff,
  VP of Marketing
• Robert S. McCormack,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Ashley Kluth,
  Sr. Mang. of Investor Relations
• Yili Kevin Xie,
  Director
• James F. Dempsey,
  Chief Scientific Officer
• International Ltd Fosun,
  
• Farhad Fred Ebrahimi,
  
• Caley Castelein,
  Director
• Brian K Roberts,
  Director
• Daniel Jeffrey Moore,
  Director
• Theodore T Wang,
  Director
• D Keith Grossman,
  Director
• Llc Fmr,
  10% owner
• Aditya Puri,
  Director
• Henry A Mckinnell,
  Director
• R Scott Huennekens,
  Director
• Ajay Bansal,
  Chief Financial Officer
• Shahriar Matin,
  Chief Operating Officer
• Advisors Llc Orbi Med Capit...,
  
• James Alecxih,
  Chief Commercial Officer
• Influence Ltd Strong,
  10% owner
• Advisors Llc Orbi Med Capit...,
  
• Joshua H. Bilenker,
  Director
• David P Bonita,
  Director
• Douglas Keare,
  Chief Operating Officer
• Mark Stephen Gold,
  Director
• Gail R Wilensky,
  Director
• Susan C Schnabel,
  Director
• Chris Raanes,
  President and CEO
• Brian Knaley,
  Sr VP and Interim CFO
• Phillip M Spencer,
  Director
• Zachary William Stassen,
  Chief Financial Officer
• B Kristine Johnson,
  Director
• William P. Mr. Burke,
  Chief Financial Officer
• Karen Prange,
  Director
• Paul Jr Ziegler,
  Chief Executive Officer
• Robert S Mc Cormack,
  SVP Gen Counsel & Corp Sec
• Scott William Drake,
  Director
• Sanket Shah,
  SVP, General Counsel
• Adam Andrew Podbelski,
  SVP, Customer Services